Actinodaphnine

Actinodaphnine

SCHEMBL674832

COc1cc2c(cc1O)CC1NCCc3cc4c(c-2c31)OCO4

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 1.00
LMNA P02545 3/20 1.00
POLB P06746 2/20 1.00
MAPT P10636 2/20 1.00
KMT2A Q03164 2/20 1.00
ALDH1A1 P00352 2/20 1.00
HPGD P15428 2/20 1.00
HTT P42858 1/20 1.00
MCL1 Q07820 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
L3MBTL1 Q9Y468 1/20 1.00
BCHE P06276 1/20 0.68
DYRK1A Q13627 1/20 0.66
PTPRCAP Q14761 2/20 0.61
TDP2 O95551 1/20 0.54
RAD52 P43351 1/20 0.54
CASP6 P55212 1/20 0.54
DRD2 P14416 4/20 0.50
DRD1 P21728 3/20 0.49
HTR2C P28335 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Actinodaphnine SCHEMBL30477775 1.00 KDM4E (1.00) KDM4ELMNAPOLBMAPTKMT2A
Actinodaphnine SCHEMBL29596257 1.00 KDM4E (1.00) KDM4ELMNAPOLBMAPTKMT2A
Actinodaphnine SCHEMBL2450424 1.00 KDM4E (1.00) KDM4ELMNAPOLBMAPTKMT2A
SCHEMBL29390321 0.92 KDM4E (0.84) KDM4ELMNAPOLBMAPTKMT2A
SCHEMBL31029804 0.83 PTPRCAP (0.76) KDM4ELMNAPOLBMAPTKMT2A
SCHEMBL11891033 0.83 KDM4E (0.71) KDM4ELMNAPOLBMAPTKMT2A
Cassythine SCHEMBL27858889 0.83 ALDH1A1 (0.71) KDM4ELMNAPOLBMAPTKMT2A
SCHEMBL5325477 0.82 ALDH1A1 (0.70) KDM4ELMNAPOLBMAPTKMT2A
SCHEMBL31029778 0.82 KDM4E (0.70) KDM4ELMNAPOLBMAPTKMT2A
Launobine SCHEMBL28948970 0.82 KDM4E (0.69) KDM4ELMNAPOLBMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023121486-A1 COMPOSITIONS AND COMPOUNDS FOR TREATING COVID-19 INTERNATIONAL PATENT HOLDINGS LLC (KN) 2023-06-29 WO claimed
US-8067401-B2 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LLC (KN) 2011-11-29 US claimed
US-20090069277-A1 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LTD. 2009-03-12 US claimed
WO-2023121486-A1 COMPOSITIONS AND COMPOUNDS FOR TREATING COVID-19 INTERNATIONAL PATENT HOLDINGS LLC (KN) 2023-06-29 WO disclosed
US-8697660-B2 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LLC 2014-04-15 US disclosed
US-20130023487-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION INTERNATIONAL PATENT HOLDINGS LLC (KN) 2013-01-24 US disclosed
US-20120190734-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION INTERNATIONAL PATENT HOLDINGS LLC (KN) 2012-07-26 US disclosed
US-8067401-B2 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LLC (KN) 2011-11-29 US disclosed
US-8067401-B2 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LLC (KN) 2011-11-29 US disclosed
US-20090069277-A1 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LTD. 2009-03-12 US disclosed
US-20090069277-A1 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LTD. 2009-03-12 US disclosed
US-20090069277-A1 Compounds and compositions for treating infection INTERNATIONAL PATENT HOLDINGS LTD. 2009-03-12 US disclosed
WO-2007134485-A1 APORPHINE AND OXOAPORPHINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF LOTUS PHARMACEUTICAL CO., LTD. (CN) 2007-11-29 WO disclosed
US-7294715-B2 Aporphine and oxoaporphine compounds and pharmaceutical use thereof LOTUS PHARMACEUTICAL CO., LTD. (TW) 2007-11-13 US disclosed
US-20060211723-A1 Aporphine and oxoaporphine compounds and pharmaceutical use thereof LOTUS PHARMACEUTICAL CO., LTD. (TW) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190734-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION RPN2, LSS, CLIC4 KDM4E 715/4885LMNA 4592/4885POLB 1879/4885
US-20130023487-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION RPN2, LSS, CLIC4 KDM4E 715/4885LMNA 4592/4885POLB 1879/4885
US-20090069277-A1 Compounds and compositions for treating infection RPN2, LSS, CLIC4 KDM4E 715/4885LMNA 4592/4885POLB 1879/4885
US-20060211723-A1 Aporphine and oxoaporphine compounds and pharmaceutical use thereof OGFRL1, THOP1, APOL1 KDM4E 4464/4885LMNA 2135/4885POLB 2996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.